For research use only. Not for therapeutic Use.
ATB 346（Cat No.:I000874） is a novel derivative of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). What sets ATB 346 apart is its ability to release hydrogen sulfide, which confers additional pharmacological benefits. ATB 346 retains the COX (cyclooxygenase) inhibitory activity of naproxen, providing anti-inflammatory effects. Moreover, it exhibits reduced toxicity compared to traditional NSAIDs. In addition to its anti-inflammatory properties, ATB 346 has shown the ability to induce apoptosis (programmed cell death) specifically in human melanoma cells, suggesting its potential as an anti-cancer agent.
| Catalog Number | I000874 |
| CAS Number | 1226895-20-0 |
| Synonyms | 4-carbamothioylphenyl 2-(6-methoxynaphthalen-2-yl)propanoate |
| Molecular Formula | C21H19NO3S |
| Purity | ≥95% |
| Target | COX; Apoptosis |
| Solubility | DMSO: ≥ 51.6 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (4-carbamothioylphenyl) 2-(6-methoxynaphthalen-2-yl)propanoate |
| InChI | InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26) |
| InChIKey | YCNMAPLPQYQJFC-UHFFFAOYSA-N |
| SMILES | CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC3=CC=C(C=C3)C(=S)N |
| Reference | </br>1:ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. De Cicco P, Panza E, Ercolano G, Armogida C, Sessa G, Pirozzi G, Cirino G, Wallace JL, Ianaro A.Pharmacol Res. 2016 Dec;114:67-73. doi: 10.1016/j.phrs.2016.10.019. Epub 2016 Oct 21. PMID: 27777130 </br>2:The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. Mostafa DK, El Azhary NM, Nasra RA.Can J Physiol Pharmacol. 2016 Jul;94(7):699-708. doi: 10.1139/cjpp-2015-0316. Epub 2016 Jan 20. PMID: 27088818 </br>3:The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Herrera BS, Coimbra LS, da Silva AR, Teixeira SA, Costa SK, Wallace JL, Spolidorio LC, Muscara MN.Med Gas Res. 2015 Feb 27;5:4. doi: 10.1186/s13618-015-0025-3. eCollection 2015. PMID: 25755876 Free PMC Article</br>4:Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. Campolo M, Esposito E, Ahmad A, Di Paola R, Paterniti I, Cordaro M, Bruschetta G, Wallace JL, Cuzzocrea S.J Neuroinflammation. 2014 Dec 4;11:196. doi: 10.1186/s12974-014-0196-1. PMID: 25472548 Free PMC Article</br>5:Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Elsheikh W, Blackler RW, Flannigan KL, Wallace JL.Nitric Oxide. 2014 Sep 15;41:131-7. doi: 10.1016/j.niox.2014.04.006. Epub 2014 Apr 18. PMID: 24747869 </br>6:A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Ekundi-Valentim E, Mesquita FP, Santos KT, de Paula MA, Florenzano J, Zanoni CI, Rodrigues L, de Nucci G, Teixeira SA, Ferreira HH, Wallace JL, Costa SK, Muscará MN.Med Gas Res. 2013 Nov 16;3(1):24. doi: 10.1186/2045-9912-3-24. PMID: 24237604 Free PMC Article</br>7:Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Wallace JL, Caliendo G, Santagada V, Cirino G.Br J Pharmacol. 2010 Mar;159(6):1236-46. doi: 10.1111/j.1476-5381.2009.00611.x. Epub 2010 Feb 1. PMID: 20128814 Free PMC Article |
